The imnunogenicity and safety of a new Haemophilus influenzae type b conjugate vaccine, PRP-T, was studied in 107 infants from the Oxford district. The vaccine was given concurrently with diphtheria, pertussis, tetanus, and polio vaccines at 2, 3, and 4 months of age. Symptoms after immunisation were recorded by a parent. Sera were obtained before the first immunisation and at 5 months of age and the antibodies were measured by both radioimmunoassay and enzyme linked immunosorbent assay (ELISA). No serious adverse reactions were observed and there was no increase in the incidence of expected minor side effects. By radioimmunoassay, the geometric mean titre of serum anticapsular antibody increased from 0-09 ,ug/ml before immunisation to 5-01 itg/ml after three immunisations. Ninety eight per cent of children had antibody concentrations consistent with protection (-.0-15 ig/mi). IgG antibody concentrations measured by ELISA correlated weli with total antibody concentrations measured by radioimmunoassay (r=0-864). These results provide encouragement that routine immunisation against H influenzae type b at 2, 3, and 4 months of age,
Haemophilus influenzae type b is a major cause of serious bacterial infection in early childhood, during which it is the most common cause of meningitis, epiglottitis, cellulitis, and septic arthritis.' Epidemiological surveillance in the Oxford region of the UK over the past seven years has underlined the continuing importance ofH influenzae type b infection.2 The cumulative risk of infection for children by their fifth birthday is one in 600.
Serum antibodies to the polyribosylribitol phosphate (PRP) capsule of H influenzae type b are protective.3 However, purified polysaccharide vaccine (composed of PRP) is poorly immunogenic in children less than 2 years old,4 the age group in which most infections occur. This age related susceptibility, first documented in the 1930s, was found to correlate with absent or low concentrations of serum antibodies to PRP, a finding that is typical of infants in their first and second years. 5 Enhancement of the immunoprotective response to polysaccharide antigen is possible through its covalent linkage (conjugation) to a carrier protein,6 which results in T cell dependency and a boostable response, thereby offering the potential of antibody responses that would protect young infants. Four maternally derived anti-PRP antibodies on the serum antibody response to PRP-T was therefore evaluated. This was done by dividing infants into two groups according to preimmunisation antibody concentrations using 0 15 ,ug/ml to divide the high and low antibody groups; postimmunisation antibody concentra- Geometri~c mean anti-PRP antibody titre (jig/ml):
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After immunisation 4-66 5-81 tions of the two groups were then compared. There was no significant differences ( Although the initial response of young-infants to PRP-T vaccine is clearly effective, the longevity of the protection is an important question and affects whether booster doses are required. Studies in Finland of PRP vaccine suggest that a serum anti-PRP antibody concentration of at least 1 [tg/ml correlates with long term protection.4 Given that over 90% of infants achieved antibody concentrations greater than 1 ,ug/ml, it is not certain that a booster dose will be required. In any case, it may be that the three dose course primes for a boostable (and thereby protective) response regardless of the absolute serum antibody concentration when the child is later exposed to H influenzae type b organisms.'7 This question may abe addressed by long term follow up of antibody concentrations and ideally by an efficacy trial with vaccinations given at 2, 3, and 4 months of age but without a booster dose in the second year of life.
Epidemiological surveillance in Oxford has shown that, of H influenzae type b disease in children under 5 years, only 6% occurs in those under 4 months whereas 42% occurs before 12 months (unpublished data). This illustrates the rapid increase in risk of infection as maternally derived antibody declines. Given 95% vaccine uptake in the new 2, 3, and 4 month schedule, immunisation has the potential to prevent up to 90% of H influenzae type b infections in young children. This translates to the potential annual prevention of 60 deaths and 1170 cases of infection in the UK.2 The encouraging immunogenicity and tolerability of PRP-T conjugate vaccine, demonstrated in this study, make it a candidate for inclusion in the routine national schedule. An open intervention study of PRP-T vaccine given at 2, 3, and 4 months of age is underway in the Oxford region. It is anticipated that 30 000 infants will be immunised and that clinical efficacy can be evaluated by late 1992 when immunisation against H influenzae type b disease is due to start in the national programme.
